Pharma Times -- AstraZeneca’s cancer drug Iressa has suffered a further setback in the UK after cost regulators rejected its use on NHS Scotland as a treatment for patients with non-small cell lung cancer.
Pharma Times -- AstraZeneca’s cancer drug Iressa has suffered a further setback in the UK after cost regulators rejected its use on NHS Scotland as a treatment for patients with non-small cell lung cancer.
